[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteoarthritis-knee\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteoarthritis-knee":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,99,0,25,[9,42,70,95,115,137,160,182,205,229,255,276,295,320,347,372,395,424,457,484,512,538,567,592,619],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100553798","analysis-of-the-pathophysiological-and-functional-state-of-the-knee-joint-100553798",false,"NCT06490770","Analysis of the Pathophysiological and Functional State of the Knee Joint","Gait-MRI-Knee","Inclusion Criteria:\n\n* Knee pain and\u002For loss of functionality\n* Kellgren-Lawrence grade less than or equal to 2\n* Arthroscopic evidence of cartilage tissue lesions\n* Evidence of cartilage and\u002For meniscal tissue degeneration and\u002For subchondral bone marrow lesions\n\nExclusion Criteria:\n\n* History\u002Fevidence of previous partial or total knee prosthesis interventions\n* Inability to provide informed consent\n* Conditions or physical disorders incompatible with the use of MRI and electrical stimulation (implanted active and passive biomedical devices, epilepsy, severe venous insufficiency in the lower limbs)","ALL","18 Years","60 Years",{"count":7,"type":21},"ESTIMATED","INTERVENTIONAL",[24],"NA","Osteoarthritis is the most common degenerative condition affecting the knee joint globally, with an incidence of about 7% of the population. In Italy, it affects approximately 3.9 million people, with a direct treatment cost of around €2.5 billion. At the joint level, osteoarthritis manifests with pain and reduced functionality, worsening as the disease progresses and severely limiting knee movement. Compounding this, osteoarthritis can impact both elderly and younger individuals due to traumatic factors.\n\nDespite its significant impact, effective treatments for osteoarthritis that address its underlying causes are still lacking, focusing mainly on symptom management. Therefore, improving diagnostic and prognostic approaches is crucial to better understand its onset and progression.\n\nMRI is a primary diagnostic tool for assessing the knee joint's pathophysiological state. It uses tissue-specific sequences to investigate joint homeostasis in detail, although it primarily provides insights into morphology, structure, and tissue composition rather than functional changes within the joint. This limitation is noteworthy because joint homeostasis involves complex interactions among biomechanical, structural, and biological processes, which are directly influenced by osteoarthritis.\n\nGait analysis provides valuable diagnostic information on joint function. By integrating sensor measurements and electronic systems with patient-specific musculoskeletal models derived from MRI morphometric data, it is possible to assess the forces and moments within the joint during specific movements.\n\nGiven that osteoarthritis affects the entire joint, employing multidisciplinary approaches can enhance diagnostic precision and provide insights into the progressive impact of degenerative conditions like osteoarthritis on joint health.",[27,28],"Osteoarthritis, Knee","Cartilage Degeneration","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2025-07-09",{"date":37,"type":21},"2027-04",{"name":39,"class":40},"Istituto Ortopedico Rizzoli","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100644699","standard-versus-novel-rfa-for-chronic-knee-pain-in-osteoarthritis-100644699","NCT07674082","Standard Versus Novel RFA for Chronic Knee Pain in Osteoarthritis","A Prospective Pilot Study Comparing Standard and Novel Radiofrequency Ablation Protocols for Chronic Knee Pain in Osteoarthritis","Inclusion Criteria:\n\n1. Any patient with knee osteoarthritis receiving knee RFA.\n2. Stable pain medications for past 1 month.\n3. Able to speak English.\n\nExclusion Criteria:\n\n1. Scheduled for knee surgery within 6 months following RFA procedure.\n2. Participating in another study that the Principal Investigator or Co-Investigators deem will interfere with the interpretation of the results.",{"count":50,"type":21},24,[24],"Brief Summary\n\nThe goal of this pilot study is to evaluate the feasibility and safety of conducting a randomized comparison of two standard-of-care knee radiofrequency ablation (RFA) techniques in adults with chronic knee pain related to knee osteoarthritis.\n\nParticipants who are already scheduled to receive knee RFA as part of their standard clinical care will be randomized to receive either a standard 3-target (standard) RFA protocol or a 6-target (novel) RFA protocol. The main purpose of this pilot study is to determine whether a future larger randomized trial comparing these two RFA approaches is feasible and safe to conduct.\n\nParticipants will complete questionnaires about pain, knee function, and stiffness at baseline and at follow-up timepoints for up to 12 months after the RFA procedure. Preliminary pain relief outcomes will also be explored to help inform the design of a future definitive trial.\n\nParticipants already scheduled for a knee RFA procedure as part of their standard of care for pain related to knee osteoarthritis will answer online survey questions about their pain for up to 12 months.",[27],[55,56,57,58,59],"radiofrequency ablation","radiofrequency","needle insertion","knee pain","pain management","NOT_YET_RECRUITING","2026-06-23",{"date":63,"type":33},"2026-06-29",{"date":65,"type":21},"2026-07-20",{"date":67,"type":21},"2029-08-20",{"name":69,"class":40},"Lawson Research Institute of St. Joseph's",{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":94},"100515037","phase-2-a-master-protocol-study-ly900028-of-multiple-intervention-specific-appendices-isas-in-participants-with-chronic-pain-100515037","NCT05986292","A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain","A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain","CPMP","Inclusion Criteria:\n\n* have a visual analog scale (VAS) pain value \\>40 and \\\u003C95 at screening and prerandomization screening.\n* have a history of daily pain for at least 12 weeks based on participant report or medical history\n* have a value of ≤30 on the pain catastrophizing scale\n* have a body mass index \\\u003C40 kilogram\u002Fsquare meter (kg\u002Fm²) (inclusive)\n* are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.\n* are willing to discontinue all medications taken for chronic pain conditions, except rescue medication for the duration of the study\n\nExclusion Criteria:\n\n* have second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia\n* have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)\n* have surgery planned during the study for any reason, related or not to the disease state under evaluation.\n* have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.\n* have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.\n* have fibromyalgia\n* have substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)\n* have any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study.\n* have a positive human immunodeficiency virus (HIV) test result at screening\n* have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening.",{"count":79,"type":21},10000,[81],"PHASE2","The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.",[27,84,85],"Diabetic Neuropathic Pain","Chronic Low-back Pain","2026-06-19",{"date":61,"type":33},{"date":89,"type":33},"2020-01-30",{"date":37,"type":21},{"name":92,"class":93},"Eli Lilly and Company","INDUSTRY",64,{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":41},"100532117","effects-of-movement-retraining-on-knee-loading-in-individuals-with-knee-osteoarthritis-100532117","NCT06208631","Effects of Movement Retraining on Knee Loading in Individuals With Knee Osteoarthritis","Effects of Haptic Movement Retraining on Osteoarthritis Progression","Inclusion Criteria:\n\n* Medial and\u002For lateral compartment knee osteoarthritis\n* Diagnosed with knee osteoarthritis of at least six months duration\n* Ambulatory without aids\n* Able to walk for at least 60 minutes\n* Typical pain rating of 1-4 on scale of 0-10\n* Able to reduce gastrocnemius muscle activation by 10% from baseline\n\nExclusion Criteria:\n\n* History of symptomatic arthritis in lower limb joints other than the knees\n* Replacement of any lower extremity joint\n* Symptoms originating from the patellofemoral joint\n* Body mass index equal to or greater than 35\n* Nerve or muscle disease associated with walking difficulty\n* History of rheumatoid arthritis, gout, or autoimmune disease\n* History of lower limb fracture or surgery requiring hospitalization\n* Pregnant",{"count":103,"type":21},31,[24],"This study investigates how well individuals with knee osteoarthritis can learn to alter their calf muscle activation using haptic biofeedback while walking and evaluates how these changes affect knee loading.\n\nPrior research has utilized musculoskeletal simulations to determine that reducing the activation of one of the calf muscles, the gastrocnemius, can have a large impact on reducing knee loading. However, this has not been tested in individuals with knee osteoarthritis. In this study, participants will be trained to alter the activation of their gastrocnemius muscle, by receiving haptic feedback after each step. The feedback will indicate how the participant changed their muscle activation relative to baseline. Some participants will train on a treadmill in the laboratory for up to two sessions, with 30 minutes of walking with feedback in each session. If a participant can learn to adjust their muscle activation in the first training session, they will be able to complete the second training session. Other participants will train outside the laboratory for one session with 30 minutes of walking with feedback to investigate changes in knee loading while using the new walking strategy during over-ground walking.\n\nThe movement data collected during the training sessions will be used as inputs to computer simulations of the musculoskeletal system to determine if walking with the new muscle activation strategy reduces knee loading.",[27],"2026-06-18",{"date":61,"type":33},{"date":110,"type":33},"2024-01-18",{"date":112,"type":21},"2026-12",{"name":114,"class":40},"Stanford University",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":17,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":135,"locationsCount":41},"100584322","radio--ko-radiotherapy-for-knee-osteoarthritis-clinical-trial-100584322","NCT06887829","Radio- KO Radiotherapy for Knee Osteoarthritis Clinical Trial","The Randomized Clinical Trial of Low-Dose Radiotherapy for Knee Osteoarthritis","Inclusion Criteria:\n\n* • patient's primary care provider is at Mayo Clinic in Rochester, MN\n\n  * age 50-100 years\n  * ICOAP pain scale A1 at least moderate intensity or B6 at least moderate intensity\n  * diagnosed with primary knee OA ICD-10 codes M17.x\n\n    o You have not had recurrent episodes of sudden onset of warmth, redness, or swelling of the affected knee\n  * physical exam findings of medial or lateral joint line tenderness on palpation that is in the same location as the knee pain.\n  * absence of primary knee pain in the pes anserine or hamstring or gastrocnemius, quadriceps, or patellar tendons on exam.\n  * radiographic Kellgren-Lawrence grade 2-3 on 4-view knee x-rays taken within the last year ability to complete surveys electronically by email\n\nExclusion Criteria:\n\n* • Kellgren-Lawrence grade 1 or 4\n\n  * pregnancy or women 54 years and younger with potential for pregnancy (if they or their partner have not had tubal ligation, hysterectomy, or vasectomy)\n  * history of ipsilateral intraarticular knee surgery\n  * use of injected corticosteroids within 3 months or hyaluronans within 6 months or within 1 month if there was no sustained improvement post-injection of either corticosteroid or hyaluronan.\n  * history of trauma to this knee in the last year that clearly caused the pain now present\n  * history of RA, gout, pseudogout, hemarthroses (eg, hemophilic arthropathy) or other inflammatory arthritis involving this knee\n  * history of symptomatic hip OA\n  * history of psychosis, personality disorder, uncontrolled affective disorder\n  * history of fibromyalgia\n  * malignancy requiring active treatment current regular use of opiate analgesics, PRP, or acupuncture for the knees","50 Years","100 Years",{"count":125,"type":21},128,[24],"The primary aim of this study is to investigate whether low-dose radiotherapy is an effective treatment to reduce the pain of knee osteoarthritis. A secondary aim is to determine whether patients experience any more measurable side effects than those receiving sham treatments.",[27],"2026-06-10",{"date":131,"type":33},"2026-06-12",{"date":133,"type":33},"2025-06-04",{"date":63,"type":21},{"name":136,"class":40},"Mayo Clinic",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":158,"locationsCount":159},"100642998","phase-2-a-chronic-pain-master-protocol-cpmp-a-study-of-ly4065967-in-participants-with-osteoarthritis-pain-100642998","NCT07641517","A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain","Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Osteoarthritis","OA07","Inclusion Criteria:\n\n* Have presence of index knee pain for more than 12 weeks at screening\n* Have an x-ray supporting diagnosis of osteoarthritis according to the American College of Rheumatology with a Kellgren-Lawrence grade 2 to 4 radiographic classification of index knee\n* Have a body mass index ≤40 kilograms per meter squared (kg\u002Fm²) (inclusive)\n* Have stable glycemic control as indicated by a glycated hemoglobin (HbA1c) less than or equal to 10 at time of screening\n\nExclusion Criteria:\n\n* Are pregnant or breastfeeding\n* Have had a surgical procedure or therapeutic injection in the affected knee within 3 months prior to screening\n* Have presence of surgical hardware or other foreign body in the index knee\n* Have ongoing complex regional pain syndrome or other concurrent medical condition that could interfere with the evaluation of pain in the index knee.\n* Have had any joint replacement of the lower extremity, such as hip, knee or ankle, in the 6 months prior to screening\n* Have an abnormal blood pressure (BP) (systolic BP greater than 140 millimeters mercury (\\>140 mm Hg) and diastolic BP\\>90 mm Hg) at screening\n* Have history or current clinically significant cardiac disease, including arrhythmia, aortic aneurysm, heart failure, current electrolyte abnormalities, or any other conditions that could predispose to arrhythmia in the judgement of the investigator","40 Years",{"count":147,"type":21},150,[81],"The main purpose of this study is to test the safety and efficacy of study drug for the treatment of knee pain due to osteoarthritis (OA). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.",[27,151],"Chronic Pain","2026-06-08",{"date":154,"type":33},"2026-06-11",{"date":156,"type":21},"2026-07",{"date":37,"type":21},{"name":92,"class":93},37,{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":181},"100580951","motion-clinical-trial-100580951","NCT06843980","MOTION Clinical Trial","Evaluation of the MISHA® Knee System for Symptom Relief in Subjects With Medial Knee Osteoarthritis Versus the Use of Non-surgical Treatment: Randomized Clinical Trial and Comparison of Therapies for Medial Knee Osteoarthritis","Key Inclusion Criteria:\n\n1. Activity exacerbated knee pain isolated to the medial compartment and not global in nature\n2. WOMAC pain ≥ 40\n3. Failed to find relief in non-surgical treatment modalities\n\nKey Exclusion Criteria:\n\n1. Large medial osteophyte(s) or considerable extruded meniscus that may interfere with the placement or function of the device\n2. Poor bone quality (e.g., bony erosion, osteopenia, osteoporosis)\n3. Ligamentous instability\n4. Active or recent knee infection\n5. Inflammatory joint disease, including sequelae of viral infections\n6. Suspected or documented allergy or hypersensitivity to cobalt, chromium, nickel or other metals\n7. History of keloid, hypertrophic or contracture scaring\n8. Propensity for restrictive scar formation or adhesions with prior procedures",{"count":168,"type":21},100,[24],"Prospective, multicenter, two-arm, 2:1 randomized controlled trial (RCT) comparing the benefits in subjects with medial knee osteoarthritis who are treated with either the MISHA Knee System or with non-surgical treatment.\n\nThis is the first randomized head-to-head study comparing outcomes from subjects treated with the MISHA Knee System.",[27],"2026-06-02",{"date":174,"type":33},"2026-06-03",{"date":176,"type":33},"2025-02-13",{"date":178,"type":21},"2030-06-30",{"name":180,"class":93},"Moximed",8,{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":41},"100638529","cryotherapy-versus-standard-care-in-reducing-opioid-consumption-after-total-knee-arthroplasty-100638529","NCT07630337","Cryotherapy Versus Standard Care in Reducing Opioid Consumption After Total Knee Arthroplasty","Efficacy of Cryotherapy Versus Standard Care in Reducing Opioid Consumption After Total Knee Arthroplasty: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 60 and 80 years\n* Scheduled to undergo primary total knee arthroplasty for knee osteoarthritis\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Revision total knee arthroplasty\n* Vascular disorders affecting the lower limbs\n* Body mass index (BMI) greater than 35 kg\u002Fm²\n* Active knee infection\n* Severe preoperative limitations in knee mobility",{"count":190,"type":21},74,[24],"The goal of this clinical trial is to learn if compressive cryotherapy can reduce postoperative opioid consumption in patients undergoing primary total knee arthroplasty. It will also evaluate whether compressive cryotherapy improves postoperative recovery compared with standard care using conventional ice application. The main questions it aims to answer are:\n\nDoes compressive cryotherapy reduce the total consumption of opioids during the first 7 days after total knee arthroplasty?\n\nDoes compressive cryotherapy reduce postoperative pain and improve early recovery compared with standard cryotherapy?\n\nResearchers will compare compressive cryotherapy using the Game Ready® device with standard care using traditional ice packs to determine whether the intervention reduces opioid consumption and improves postoperative outcomes.\n\nParticipants will:\n\nBe randomly assigned to receive compressive cryotherapy or standard cryotherapy with ice packs after surgery.\n\nApply the assigned treatment four times per day during the first 7 postoperative days.\n\nRecord daily pain levels using a visual analog scale (VAS) and document opioid consumption in a pain diary.\n\nAttend a follow-up visit on postoperative day 7 for evaluation of knee swelling, hematoma size, and recovery using the QoR-15 questionnaire.",[27,194,195],"Postoperative Pain","Total Knee Arthroplasty","2026-06-01",{"date":198,"type":33},"2026-06-05",{"date":200,"type":33},"2026-02-01",{"date":202,"type":21},"2027-06-01",{"name":204,"class":40},"Hospital Italiano de Buenos Aires",{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":228},"100632101","phase-3-amaze-6-a-research-study-investigating-how-well-the-medicine-nnc0487-0111-helps-people-with-excess-body-weight-and-knee-osteoarthritis-lose-weight-and-reduce-pain-100632101","NCT07509307","AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 6)","AMAZE 6","Key Inclusion Criteria:\n\n* Male or female (sex at birth)\n* Age 18 years or above at the time of signing the informed consent\n* Clinical diagnosis of knee osteoarthritis (OA) (American College of Rheumatology criteria) with radiographic changes (Kellgren Lawrence \\[KL\\] grades 2 to 4 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees is equal, the target knee joint will be the dominant leg\n* Symptomatic knee OA with first appearance of pain in the target knee \\> 90 days prior to screening and pain in the target knee for \\> 15 days over the prior 30 days\n* Willingness to complete a 72-hour washout period of analgesics before all visits involving WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) questionnaire (acetaminophen 4 grams (g)\u002Fday is allowed as rescue medication up until 24 hours before those visits)\n\nKey Exclusion Criteria:\n\n* Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol\u002Fmol) as measured by the central laboratory at screening\n* History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records\n* Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening\n* Any joint prosthesis or joint replacement in target knee\n* Arthroscopy or injections into target knee within the last 90 days prior to screening\n* Any other joint disease in target knee including gout and pseudogout",{"count":214,"type":21},400,[216],"PHASE3","This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.",[219,220,27],"Obesity","Overweight",{"date":172,"type":33},{"date":223,"type":33},"2026-04-20",{"date":225,"type":21},"2028-08-14",{"name":227,"class":93},"Novo Nordisk A\u002FS",81,{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":17,"minAge":145,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":41},"100552830","phase-4-knee-osteoarthritis-treatment-with-zilretta-vs-kenalog-in-the-context-of-type-ii-diabetes-100552830","NCT06478186","Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes","RCT to Evaluate the Effects of Zilretta (Triamcinolone Acetonide- Extended Release) and Kenalog (Triamcinolone Acetonide- Immediate Release) on Blood Glucose in Subjects With Osteoarthritis of the Knee and Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* 1\\. Written consent to participate in the study. 2. Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions.\n\n  3\\. Male or female ≥40 years of age. 4. Females with negative pregnancy test, who are not breastfeeding and have no intention to become pregnant during the time from screening through EOS.\n\n  5\\. Type 2 DM for at least 1 year prior to Screening. 6. Currently being treated with injectable (except insulin) and\u002For oral antidiabetic agents with stable doses for at least 1 month prior to Screening.\n\n  7\\. HbA1c 6.5-9% (in past 8 weeks). 8. Estimated glomerular filtration rate (eGFR) ≥50 mL\u002Fmin\u002F1.73 m2. (in past 8 weeks) 9. Triglycerides \\\u003C500 mg\u002FdL (in past 8 weeks) 10. Painful symptoms associated with OA of the knee for ≥6 months prior to Screening (NRS of 4-9 during most of the 30 days prior to enrollment).\n\n  11\\. Currently meets modified ACR criteria (clinical and radiological) for OA (Altman et al, 1986) as follows:\n  1. Knee pain\n  2. At least 1 of the following:\n\n     * Stiffness \\\u003C30 minutes\n     * Crepitus\n  3. Osteophytes 12. Index knee pain more than 15 days over the last month (as reported by the subject).\n\n     13\\. Kellgren-Lawrence Grade 2-4. 14. Willingness to wear a CGM device uninterrupted for 24 hours per day throughout the required time during the study and comply to the correct use requirements of CGM throughout the trial and perform self BG checks as directed.\n\n     15\\. Adequate BG data collected during the pretreatment phase (Day -10 through Day -1) ≥70% data available.\n\n     Exclusion Criteria:\n\n     Disease-related Criteria\n     1. Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease.\n     2. History of infection in the index knee joint.\n     3. Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening.\n     4. Presence of surgical hardware or other foreign body in the index knee.\n     5. Unstable joint (such as a torn anterior cruciate ligament) within 12 months of Screening.\n     6. Moderate or severe kidney, liver, or thyroid disease.\n     7. Glaucoma.\n     8. Active cancer. Previous or Concomitant Treatment-related Criteria\n     9. IA corticosteroid (investigational or marketed) in any joint within 3 months of Screening.\n     10. IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening.\n     11. IV or intramuscular (IM) corticosteroids (investigational or marketed) within 3 months of Screening.\n     12. Oral corticosteroids (investigational or marketed) within 1 month of Screening.\n     13. Inhaled, intranasal, or topical corticosteroids (investigational or marketed) within 2 weeks of Screening.\n     14. Any other IA investigational device, drug\u002Fbiologic within 6 months of Screening or 5 half-lives (whichever is longer).\n     15. Prior arthroscopic or open surgery of the index knee within 12 months of Screening.\n     16. Planned\u002Fanticipated surgery of the index knee or any other surgery during the study period.\n     17. Use of acetaminophen, or acetaminophen-containing products, from Screening through Day 14 (completion of post-treatment BG monitoring).\n     18. Subjects on Coumadins with INR ≥5 will be excluded (Bashir et al, 2015) Subject-related Criteria\n     19. Known hypersensitivity to any form of triamcinolone.\n     20. History of sarcoidosis or amyloidosis.\n     21. Active or history of malignancy within the last 3 years, except for resected basal cell carcinoma, squamous cell carcinoma of the skin, or effectively managed cervical carcinoma.\n     22. Known active or quiescent systemic fungal, bacterial (including tuberculosis), viral, or parasitic infections or ocular herpes simplex.\n     23. Any infection requiring IV antibiotics within 4 weeks of Screening or infection requiring oral antibiotics within 2 weeks of Screening.\n     24. History of osteomyelitis.\n     25. Known or clinically suspected infection with human immunodeficiency virus (HIV) or hepatitis B or C viruses.\n     26. Requiring or likely to require treatment with corticosteroids during the study period based on subject medical history.\n     27. History or active Cushing's or Addison's syndrome.\n     28. Active substance abuse (drugs or alcohol), history of chronic substance abuse within the last year, or prior chronic substance abuse judged by the Investigator likely to recur during the study.\n     29. Skin breakdown at the knee where the injection would take place.\n     30. Use of immunomodulators, immunosuppressives, or chemotherapeutic agents within 2 years of Screening.\n     31. Receipt of a live or live attenuated vaccine within 3 months of Screening.\n     32. Any other clinically significant psychiatric acute or chronic medical conditions that, in the judgment of the Investigator, would preclude the use of an IA corticosteroid or NSAIDs or that could compromise subject safety, limit the subject's ability to complete or adhere to the study, and\u002For compromise the objectives of the study.",{"count":237,"type":21},120,[239],"PHASE4","A Phase 2 Randomized Study to Evaluate the Effects of triamcinolone acetonide extended-release (TA-ER; Zilretta) vs. triamcinolone acetonide immediate-release (TA-IR; Kenalog) on Blood Glucose Levels in Diabetic Subjects with Knee Osteoarthritis. Subjects should have Type 2 Diabetes Mellitus (T2DM) with HbA1C ≤9 that is managed without insulin and have been diagnosed with symptomatic unilateral or bilateral osteoarthritis (OA) of the knee, based on clinical and radiological criteria (if bilateral, then a target knee will be selected).Total study duration for individual subject will be about 4 months, which includes 3 weeks of Screening period, 10 days of pretreatment phase, treatment day, and 12 weeks of post-treatment period.",[27,242],"Diabetes Mellitus, Type 2",[244,245],"Zilretta","Kenalog","2026-05-27",{"date":248,"type":33},"2026-05-28",{"date":250,"type":33},"2024-08-16",{"date":252,"type":21},"2027-01-16",{"name":254,"class":40},"University of Kansas Medical Center",{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":17,"minAge":145,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":22,"phases":264,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":41},"100573265","effects-of-including-interferential-current-in-a-therapeutic-exercise-program-in-individuals-with-knee-osteoarthritis-100573265","NCT06744036","Effects of Including Interferential Current in a Therapeutic Exercise Program in Individuals With Knee Osteoarthritis","Inclusion Criteria:\n\n* both sexes\n* between 40 years old and 75 years old\n* with a clinical diagnosis of unilateral KOA\n* Who has had knee pain for more than 3 months\n* With a minimum score of 3 points on the numerical pain scale\n* Morning stiffness for less than 30 minutes\n* Crepitus\n* Bone tenderness and absence of palpable heat\n\nExclusion Criteria:\n\n* Hip OA\n* Severe osteoporosis\n* Fibromyalgia\n* Clinical history of tumors or cancer\n* Active inflammatory joint diseases (rheumatoid arthritis, gout)\n* Undergoing any joint replacement in the lower extremity\n* Neurological diseases (Parkinson's disease, stroke\n* Multiple sclerosis\n* muscular dystrophies\n* Diseases involving motor neurons\n* Alzheimer's disease\n* Infected wounds or osteomyelitis in the knee region\n* Deep vein thrombosis or thrombophlebitis\n* Sensory alteration in the lower limbs\n* Cognitive and cardiopulmonary impairment that may prevent or limit the execution of exercises\n* Use of a walking assistance device\n* History of recent knee trauma\n* Having undergone any form of treatment involving physical therapy\n* intra-articular corticosteroids\n* anti-inflammatory drugs\n* opioid medication or chondroprotective in the six months before the start of the interventions","75 Years",{"count":263,"type":21},138,[24],"The first-line treatment for knee osteoarthritis (KOA) in terms of pain and functionality is physical exercise. The use of interferential current (IC) associated with other resources may be beneficial in reducing pain intensity and improving functionality. However, the effects of its simultaneous use with therapeutic exercise have not yet been fully established. The aim of this project will be to evaluate the effects of including IC in a therapeutic exercise program in relation to pain intensity, functionality, self-efficacy, maximum voluntary contraction and overall perceived effect in individuals with KOA. Therefore, research participants of both sexes, between 40 and 75 years old, with a clinical diagnosis of unilateral KOA, who have knee pain for more than 3 months, with a minimum score of 3 points on the numerical pain scale, morning stiffness for less than 30 minutes, crepitation, bone sensitivity, and absence of palpable heat will be recruited. The research participants will be randomized into three groups: therapeutic exercises (n=46) and therapeutic exercises + IC (n=46) and therapeutic exercises + IC placebo (n=46). Eight consecutive weeks of treatment will be carried out. The research participants will be evaluated before the intervention, after the end of the intervention of eight consecutive weeks of intervention and after four weeks at the end of the last week of intervention, through the instruments: numeric pain scale (NPS), Knee Injury and Osteoarthritis Outcome Score (KOOS), patient-specific functional scale (EFEP), Pain self-efficacy questionnaire (PSEQ), maximum voluntary isometric contraction (MVIC), 30-second sit-to-stand test (TSL30s), global perception scale (EPG). For data analysis, a normality test will be used to verify the distribution of the data and a statistical test appropriate for the appropriate intra and inter-group comparisons, thus considering two factors in the comparisons, time and group. A significance level of 5% will be adopted.",[27],"2026-05-21",{"date":269,"type":33},"2026-05-22",{"date":271,"type":33},"2025-01-20",{"date":273,"type":21},"2026-07-28",{"name":275,"class":40},"University of Nove de Julho",{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":17,"minAge":145,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":41},"100530458","effects-of-including-a-chronic-pain-neuroscience-education-program-for-individuals-with-knee-oa-100530458","NCT06187038","Effects of Including a Chronic Pain Neuroscience Education Program for Individuals With Knee OA","Effects of Including a Chronic Pain Neuroscience Education Program for Individuals With Knee OA: Randomized, Blinded Clinical Trial","Inclusion Criteria:\n\n* A clinical diagnosis of knee osteoarthritis (knee pain for \\> 3 months\n* Morning stiffness \\\u003C30 minutes\n* Crepitus\n* Bone tenderness, and absence of palpable heat and\u002For diagnosis established radiographically (determined by Kellgren and Lawrence grade 1 to 3 on a scale 1 up to 4)\n\nExclusion Criteria:\n\n* Hip OA\n* severe osteoporosis\n* Fibromyalgia\n* Medical history of tumors or cancer\n* Active inflammatory joint diseases (rheumatoid arthritis, gout)\n* Undergoing any lower extremity joint replacement\n* Neurological diseases (Parkinson's disease, stroke, Multiple Sclerosis, muscular dystrophy, motor neuron disease, Alzheimer's disease, cognitive and cardiopulmonary impairment that may prevent or limit the performance of exercises, use of a gait assistance device, history of recent knee trauma.\n* Having undergone any form of treatment involving physiotherapy, intra-articular corticosteroids, anti-inflammatories or chondroprotective in the last six months","80 Years",{"count":285,"type":21},92,[24],"Research participants diagnosed with knee osteoarthritis will be randomized through a draw using sealed opaque envelopes indicating two groups: 1. therapeutic exercises, 2. therapeutic exercises + chronic pain neuroscience education program. The primary outcome will be functional performance using a patient-reported measure, the Knee Injury and Osteoarthritis Outcome Score (KOOS).\n\nThe selected secondary outcomes will be pain intensity by the numerical pain scale (END), physical function reported by the patient by the patient-specific functional scale (EFEP), Pain self-efficacy questionnaire (PSEQ), functional mobility by the timed up and test (TUG), general effect perceived through the global perception scale (EPG), muscle strength through Maximum Voluntary Isometric Contraction (MVIC) and functionality and disability through the World Health Organization Disability Assessment Schedule (WHODAS).",[27],{"date":269,"type":33},{"date":291,"type":33},"2024-05-28",{"date":293,"type":21},"2026-12-15",{"name":275,"class":40},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":303,"sex":17,"minAge":18,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":306,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":41},"100352525","total-knee-arthroplasty-fast-track-protocol-is-the-future-100352525","NCT03869996","Total Knee Arthroplasty: Fast Track Protocol is the Future?","Randomised Controlled Study Comparing Fast Track and Standard Care Protocol on the Functional Outcomes and Hospital Stay of Total Knee Arthroplasty","FastTrack-G","Inclusion Criteria:\n\n* patients affected by knee osteoarthritis, eligible for primary total knee arthroplasty\n* BMI \\\u003C 32\n* Time up ang go test \\\u003C\u002F= 12 seconds\n* American Society of Anesthesiologists physical status classification system (ASA) \\\u003C\u002F= 2\n* preoperative hemoglobin (HB) \\>13 g\u002Fdl\n* patients eligible for spinal anesthesia\n* presence of a care-giver\n\nExclusion Criteria:\n\n* psychiatric diseases\n* preoperative use of crutches\n* ASA \\> 3\n* preoperative HB \\\u003C 13 g\u002Fdl",true,"78 Years",{"count":94,"type":21},[24],"Fast-track total knee arthroplasty (TKA) is a well-established concept including optimized logistics and evidence-based treatment, focusing on minimizing surgical stress and improved post-operative recovery. The aim of this protocol is to compare the standard care and fast track total knee arthroplasties in terms of functional and subjective outcomes, hospital staying, number of transfusions and analgesic consumption.",[27,309],"Arthropathy of Knee",[311,312],"fast track care","total knee arthroplasty","2026-05-20",{"date":269,"type":33},{"date":316,"type":33},"2019-02-25",{"date":318,"type":21},"2026-11-01",{"name":39,"class":40},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":328,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":334,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":346},"100565566","is-non-surgical-care-using-treat-to-target-multimodal-medical-strategies-able-to-delay-or-avoid-total-knee-replacement-100565566","NCT06643845","Is Non Surgical CaRE Using Treat to Target Multimodal meDIcal Strategies aBLE to Delay or Avoid Total Knee Replacement?","Is Non Surgical CaRE Using Treat to Target Multimodal meDIcal Strategies aBLE to Delay or Avoid Total Knee Replacement? (INCREDIBLE)","INCREDIBLE","Inclusion Criteria:\n\n* Age 18-90 years old\n* Femoro-tibial osteoarthritis Kellgren stage stage≥ 2 without laxity in extension;\n* A proposal of total knee replacement by a surgeon;\n* No corticosteroid joint injection within 3 months;\n* Visual analogic score pain (VAS) \\>40\u002F100 but \\\u003C90\u002F100 or Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index function sub scale \\>40\u002F100 at inclusion;\n* Wish to discuss medical care;\n* Able to consent and having signed a consent form.\n\nExclusion Criteria:\n\n* Contraindication or no indication to surgery or medical care (severe infection for example)\n* Inflammatory arthritis\n* Lack of social insurance\n* Symptomatic (VAS pain \\>40) contralateral knee or hip osteoarthritis (with or without replacement)\n* Pregnant or breastfeeding woman\n* Patient under court protection, guardianship, curatorship\n* Patient deprived of liberty","90 Years",{"count":330,"type":21},1000,[24],"Knee is the most common site of osteoarthritis. Treatment of knee osteoarthritis starts with a full course of medical therapy, followed by surgery to replace the knee with a prosthesis if this strategy fails, or in advanced cases. However, the new recommendations of the French rheumatology society, which evaluate the various treatments and position them in the treatment plan, are not well known, and the definition of a complete treatment remains unclear. The vast majority of patients are therefore referred to a surgeon after having tried a small part of the therapeutic arsenal (generally analgesics and corticosteroid or hyaluronic acid infiltrations). The goal of this study is to to select patients most likely to gain from surgery and to develop strategies that avoid the need for major surgery.",[27],[335,336,337],"Surgery","Arthroplasty","Total knee replacement","2026-05-19",{"date":269,"type":33},{"date":341,"type":33},"2025-10-17",{"date":343,"type":21},"2031-04",{"name":345,"class":40},"University Hospital, Brest",21,{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":359,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":371},"100586594","phase-3-a-study-to-investigate-the-treatment-effect-of-subcutaneous-injections-of-pentosan-polysulfate-sodium-compared-with-placebo-in-adult-participants-with-knee-osteoarthritis-pain-100586594","NCT06917404","A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.","A Phase 3, Randomised, Double-Blind, Placebo-Controlled Multi-Centre Study to Evaluate the Treatment Effect of Pentosan Polysulfate Sodium Compared to Placebo in Participants With Knee Osteoarthritis Pain","Inclusion Criteria:\n\n1. Participant must be ≥18 years of age inclusive, at the time of signing the informed consent.\n2. Clinical diagnosis of OA in the index knee by American College of Rheumatology 1986 criteria.\n3. Radiographic diagnosis (confirmed by radiologist) of knee OA classified K-L grade 2, 3, or 4 on standing anterior-posterior X-ray of the index knee.\n4. Participant is unresponsive for at least 6 months preceding Screening to any two combinations of OA therapies (one from each A and B) within the last 12 months that include: A.) conservative non-pharmacologic therapy (exercise, weight loss, physical therapy) or simple analgesics (e.g., acetaminophen) and B.) pharmacological treatment (topical or oral NSAIDs \\[or cyclooxygenase (COX) inhibitor\\], or intra-articular \\[IA\\] injections), or participant is unable to take NSAIDs because of contraindication or inability to tolerate.\n5. Average daily pain (ADP) numerical rating scale (NRS) score of 4-9 in the index knee at Screening.\n6. Baseline average weekly ADP NRS score of 4-9 in the index knee in the 7 days prior to randomization.\n7. No more than one 24-hr average pain score (0-10 NRS) reported as \"10\" during the 7 days prior to Day 1.\n8. Body mass index of ≥18.0 to ≤39.0 kg\u002Fm2.\n9. Female subjects of childbearing potential and Male subjects must agree to comply with protocol specified contraceptive requirements\n10. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n11. Completion of at least 11 out of 14 ADP NRS scores for at least 14 days prior to randomisation.\n12. Current non-pharmacologic treatment regimen for knee OA (excluding knee brace) must be stable for at least 2 weeks before Day 1 and remain stable throughout the study. Participant must be willing to abstain from starting a new or changing their non-pharmacologic treatment regimen for the duration of the study.\n13. Willing to stop treatment with oral and topical NSAIDs, and all other systemic pain medications (except allowed rescue medication) from 2 weeks before Day 1 to end of study.\n14. Agrees to use acetaminophen\u002Fparacetamol or topical analgesics (topical NSAIDs are prohibited) as rescue therapy if required.\n\nExclusion Criteria:\n\n1. History of idiopathic or immune-mediated thrombocytopenia including history of HIT with or without thrombosis.\n2. History of major bleeding disorders including haemophilia.\n3. Currently active or recent history (within preceding 12 months) of a gastric or duodenal ulcer, or suspicion of gastrointestinal tract bleeding.\n4. Recent cerebral bleeding or operation on brain, spine, or eyes within 12 months of Day 1.\n5. Spinal anaesthesia within 14 days of Day 1.\n6. Fibromyalgia, regional pain caused by lumbar or cervical compression with radiculopathy, or other moderate to severe pain disorder that may confound assessments or self-evaluation of the pain associated with osteoarthritis. Participants with a present (current) history of sciatica are not eligible for participation. Participants with a history of sciatica who have been asymptomatic for ≥3 months and who have no evidence of radiculopathy or sciatic neuropathy on thorough neurologic examination are eligible for participation.\n7. History of other disease that may involve the index knee, including inflammatory joint disease such as rheumatoid arthritis (RA), seronegative spondyloarthropathy (e.g., ankylosing spondylitis, psoriatic arthritis, inflammatory bowel disease-related arthropathy), crystalline disease (e.g., gout), endocrinopathies, metabolic joint diseases, lupus erythematosus, joint infections, Paget's disease, or tumours.\n8. History of hypersensitivity to PPS, heparin or heparin-like drugs, or drugs of a similar chemical or pharmacological class.\n9. Predisposition to hypersensitivity due to multiple (2 or more) atopic diseases (such as atopic eczema, asthma, and chronic allergic rhinitis and\u002For rhinoconjunctivitis) or multiple (2 or more) severe allergies.\n10. Allergy or contraindication to tetracosactide (Synacthen®), cosyntropin (Cortrosyn®).\n11. Allergy or contraindication to gadolinium.\n12. Chronic medical conditions including but not limited to those stated below requiring medical regime changes within 60 days before Day 1.\n\n    Concurrent unstable peripheral, cardiac, and cerebral vascular disease, poorly controlled chronic obstructive pulmonary disease and asthma, coagulopathies, uncontrolled neurological conditions, active tuberculosis, active infections, symptomatic cardiac arrhythmias, adrenal insufficiency (primary or central), nephrotic syndrome, cirrhosis (Child-Pugh stage B or C), Gilbert syndrome, uncontrolled diabetes, and uncontrolled hypothyroidism or hyperthyroidism, or mental or emotional disorders that preclude reliable study participation.\n13. History of pituitary irradiation or recent (within 1 year) history of transsphenoidal surgery.\n14. Any cancer within the previous 5 years, except for basal cell carcinomas.\n15. History or current autoimmune polyglandular syndromes.\n16. Presence of any underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely that the participant will comply with the protocol or complete the study per the protocol.\n17. Current treatment with anticoagulants or antiplatelet drugs within 2 weeks before Day 1, excluding aspirin ≤150 mg\u002Fday.\n18. Previous treatment with PPS in any form.\n19. Current or recent (within 90 days before Day 1) immunosuppressive or immunomodulatory (with immunosuppressive effects) systemic therapy including but not limited to oral, inhaled, intranasal, intra-articular (IA) and topical corticosteroids (occasional use of topical, inhaled or intranasal corticosteroids is acceptable).\n20. Use of NSAIDs with 2 weeks before Day 1.\n21. Use of opioids within 6 weeks before Day 1.\n22. Use of glucosamine or chondroitin within 6 weeks before Day 1.\n23. Use of bisphosphonates and denosumab within 12 weeks before Day 1.\n24. Use of iloprost within 12 weeks before Day 1.\n25. Use of a knee brace on the index knee within 2 weeks before Day 1.\n26. Systemic steroids administered intravenously, intramuscularly, or orally for OA or other indications within 8 weeks before Day 1.\n27. Intra-articular (IA) injections to the index knee: steroids within 12 weeks before Day 1; hyaluronic acid (HA) or any other IA injections within 24 weeks before Day 1.\n28. Stem cells or platelet-rich plasma within 12 months of Day 1.\n29. Cannabinoids within 30 days before Day 1.\n30. Use of individual vitamins and dietary supplements known to alter haemostasis within 2 weeks before Day 1, including ajoene, birch bark, cayenne, Chinese black tree fungus, cumin, evening primrose oil, feverfew, garlic, ginger, ginkgo biloba, ginseng, grapeseed extract, milk thistle, omega 3 fatty acids, onion extract, St. John's wort, turmeric, vitamins C and E, vitamin K, (multivitamins allowed).\n31. Known exposure to heparin within the last 100 days as determined by history of drug use or history of the following medical conditions or interventions: cardiac bypass surgery or thromboembolic disease.\n32. Treatment with dehydroepiandrosterone sulfates (DHEA-S) within 6 weeks before Day 1.\n33. Chronic use of oral glucocorticoid receptor antagonists or cortisol synthesis inhibitors within 12 weeks before Day 1.\n34. Biotin within 72 hours before Screening.\n35. Megestrol acetate within 6 weeks before Day 1.\n36. Participation in another clinical trial or administration of any IP or experimental product within 24 weeks or 5 half-lives (whichever is longer) before Day 1.\n37. Activated partial thromboplastin time \\[aPTT\\]) \\> 36 seconds, platelets \\\u003C150,000\u002FμL, or liver enzyme tests (aspartate aminotransferase \\[AST\\] or alanine aminotransferase \\[ALT\\]) ≥ 2 × ULN at Screening.\n38. Total bilirubin ≥1.5 ULN.\n39. Active or chronic hepatitis B virus, hepatitis C virus, or uncontrolled HIV infection (detectable virus or diagnosis of AIDS); participants with HIV infection must be on chronic suppressive antiviral medication.\n40. Evidence of any of the following conditions in any screening imaging: excessive malalignment (≥10 degrees varus or valgus) of the knee, subchondral insufficiency fracture (SIF), osteonecrosis\u002Fbone infarct, osteochondritis dissecans, stress or acute fracture, atrophic OA, pathologic fracture, primary or metastatic tumour, infectious arthritis or osteomyelitis, chronic or acute, Charcot's knee joint, synovial chondromatosis, certain posterior root tears of the meniscus, bone contusion, bone marrow oedema syndrome, bone marrow infiltration, gout, severe chondrocalcinosis, other arthropathies (e.g., RA, psoriatic arthritis), systemic metabolic bone disease (e.g., Paget's disease, metastatic calcifications) or other conditions identified by a radiologist or Medical Monitor which may interfere with a participant's assessment of pain.\n41. Any clinically significant abnormalities on clinical chemistry, haematology, urinalysis, physical examination, medical history, or vital signs as judged by the Investigator (at Screening).\n42. Resting, supine blood pressure (BP) ≥160 mmHg in systolic pressure or ≥100 mmHg in diastolic pressure at Screening. If a participant is found to have uncontrolled and\u002For untreated significant hypertension at Screening and antihypertensive treatment is initiated, assessment for study eligibility should be deferred until BP and antihypertensive medication have been stable for at least 1 month. For participants with previously diagnosed hypertension, antihypertensive medications must be stable for at least 1 month before Screening.\n43. Any macular findings on clinical examination or imaging suggestive of: moderate or advanced dry macular degeneration, geographic atrophy, moderate or advanced myopic degeneration, wet macular degeneration, pattern dystrophy or other pigmentary maculopathy, moderate or severe diabetic or hypertensive retinopathy, recent retinal vascular occlusion, macular hole or advanced epiretinal membrane with associated macular oedema, retinal dystrophy, toxic retinal maculopathy, chronic central serous retinopathy, presence of significant subretinal or intraretinal fluid (OCT finding), presence of vitelliform or vitelliform-like macular changes (OCT and clinical finding), severe maculopathy not otherwise specified.\n44. Morning cortisol \\\u003C3 μg\u002FdL.\n45. Adrenocorticotropic hormone (ACTH) \\\u003C10 pg\u002FmL.\n46. US\u002FCanada only: Morning cortisol ≥3 μg\u002FdL and \\\u003C10 μg\u002FdL and peak cortisol (by ACTH stimulation \\[250 μg, IM\\] test) \\\u003C18 μg\u002FdL at both 30 min and 60 min post stimulation.\n47. Current hyperkalaemia and\u002For hyponatremia.\n48. Contraindication to MRI.\n49. Largely or wholly incapacitated (e.g., bedridden or confined to a wheelchair, permitting little or no self-care).\n50. Major surgery or anticipated surgery during the study.\n51. Currently hospitalised or any planned hospitalizations during the study.\n52. Plan for total knee reconstruction in affected knee(s) during the study.\n53. Knee surgery or trauma to the index knee within 1 year before Day 1.\n54. A history of drug or alcohol abuse and\u002For dependence within the 12 months before Screening that, in the opinion of the Investigator, may affect participant ability to comply with study requirements.\n55. An employee of the Sponsor, clinical research organisation(s), or research site personnel directly affiliated with this study or their immediate family members defined as a spouse, parent, sibling, or child, whether biological or legally adopted.",{"count":355,"type":21},466,[216],"The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee OA pain.\n\nStudy details include:\n\n* The study duration will be up to 64 weeks.\n* The treatment duration will be 6 weeks.\n* The visit frequency will be twice weekly during treatment.\n* The visit\u002Fcontact frequency will be every 4-6 weeks during the 52-week Follow-up period.\n* Approximately 466 participants will be enrolled into this study.",[27],[360,361],"osteoarthritis","knee","2026-05-06",{"date":364,"type":33},"2026-05-08",{"date":366,"type":33},"2025-05-29",{"date":368,"type":21},"2027-07",{"name":370,"class":93},"Paradigm Biopharmaceuticals Ltd.",56,{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":17,"minAge":379,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":382,"phases":4,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":41},"100637989","mobile-technology-to-measure-knee-health-in-osteoarthritis-100637989","NCT07580222","Mobile Technology to Measure Knee Health in Osteoarthritis","Using Mobile Technology to Extract Mechanical Markers of Joint Health and Function in Early Knee Osteoarthritis","Inclusion Criteria:\n\n* Veteran and non-Veterans\n* males and females\n* diagnosed with early knee osteoarthritis\n* qualified for and participated in the Precision Assessment of Platelet Rich Plasma for Joint Preservation study (ClinicalTrials.gov ID: NCT03460236)\n* able and willing to provide informed consent for follow-up study\n\nExclusion Criteria:\n\n* symptomatic OA in joints other than the knee in the lower body\n* joint replacement\n* rheumatic disease\n* BMI \\> 35 kg\u002Fm\\^2\n* severe systematic disease defined as American Society of Anesthesiologists (ASA) 3 or above\n* pregnant or intending to become pregnant during the study","30 Years",{"count":381,"type":21},47,"OBSERVATIONAL","Veterans face a high prevalence of knee osteoarthritis (OA), but current diagnostic methods often miss early stages when interventions are more effective. This project will evaluate smartphone-based motion capture via OpenCap to measure joint mechanics in knee OA patients during functional activities, comparing its performance to a conventional motion capture system, patient-reported symptoms, and knee joint structure. The findings will have the potential to enable clinicians to trial OpenCap in its current form, provide insights into tracking joint health, and guide refinements to advance toward earlier diagnosis of knee OA by complementing symptom assessments with measures of joint mechanics.",[27],"2026-05-05",{"date":387,"type":33},"2026-05-12",{"date":389,"type":33},"2026-04-01",{"date":391,"type":21},"2028-03-31",{"name":393,"class":394},"VA Office of Research and Development","FED",{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":123,"enrollmentInfo":403,"targetDuration":4,"studyType":22,"phases":404,"briefSummary":405,"conditions":406,"keywords":411,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":41},"100527265","promoting-sleep-to-alleviate-pain---arthroplasty-100527265","NCT06145516","Promoting Sleep to Alleviate Pain - Arthroplasty","Preoperative Sleep-promotion to Achieve Improved Postoperative Pain Control and Recovery: a Randomized, Controlled Trial","PROSAP-A","Inclusion Criteria:\n\n* age ≥18 years\n* insomnia severity index score \\>10\n* fulfill DSM-V criteria for persistent insomnia disorder\n* average pain numerical rating scale (NRS) score ≥4 (scale 0 - 10) and\u002For movement-related pain NRS score ≥4 after 5 minutes walking\n* scheduled to undergo primary (first-time, i.e., not revision surgery) TKA or THA due to osteoarthritis\n\nExclusion Criteria:\n\n* uncontrolled medical disorders\n* nightshift work\n* ongoing major depressive disorder, bipolar disorder, psychotic disorder, substance dependence\n* current history or high likelihood of primary sleep disorders (other than insomnia), including obstructive sleep apnea syndrome, narcolepsy, nocturnal myoclonus\n* severely impaired vision (precluding ability to take part of study interventions)",{"count":168,"type":21},[24],"PROSAP-A is a perioperative randomized, controlled trial with a 12-month follow-up period after total knee arthroplasty (TKA) or total hip arthroplasty (THA), aiming to investigate both acute and long-term postoperative effects of preoperative sleep-promotion. Participants with clinically significant insomnia symptoms will be randomized to a brief, hybrid version of cognitive behavioral therapy for insomnia (CBT-I) or sleep education therapy, administered over a 4-week period, prior to surgery. The primary objective is to evaluate effects of preoperative sleep-promotion on acute postoperative pain control. Secondary objectives include evaluation of postoperative sleep, recovery, mental health, cognitive function and alterations in blood biomarkers.",[27,407,408,335,409,410],"Osteoarthritis, Hip","Insomnia","Pain, Postoperative","Postoperative Complications",[360,312,412,413,414,415],"total hip arthroplasty","insomnia","sleep disturbance","postoperative pain","2026-04-29",{"date":362,"type":33},{"date":419,"type":33},"2025-09-01",{"date":421,"type":21},"2030-12-01",{"name":423,"class":40},"Uppsala University",{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":22,"phases":434,"briefSummary":435,"conditions":436,"keywords":444,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":452,"leadSponsor":454,"locationsCount":41},"100635374","manual-arthroplasty-versus-velys-robotic-assisted-solution-functional-alignment-arthroplasty-for-knee-osteoarthritis-100635374","NCT07551856","Manual Arthroplasty Versus VELYS Robotic-Assisted Solution Functional Alignment Arthroplasty for Knee Osteoarthritis","Manual Arthroplasty Versus VELYS Robotic-Assisted Solution Functional Alignment Arthroplasty for Knee Osteoarthritis (The MARVEL Project): A Pragmatic, Multicentre, Blinded Randomised Controlled Trial With Multi-domain Investigations","MARVEL Project","Inclusion Criteria:\n\n* Aged \\>18 years\n* Primary knee OA\n* Requiring TKA\n* Suitable for either raTKA or mTKA\n* Capable to provide written informed consent\n* Capable and willing to complete outcome measures throughout study period\n\nExclusion Criteria:\n\n* Inflammatory arthritis\n* Significant symptomatic hip, ankle, or contralateral knee OA\n* Prior TKA or major injury or major surgery on the index knee\n* Neuromuscular gait disorders\n* BMI \\>45 kg\u002Fm2\n* Coronal plane deformity \\>15° varus\u002Fvalgus on pre-op HKA radiograph\n* Fixed flexion deformity greater than 15°\n* Bone loss likely to require non-standard implants (e.g. stems, augments)\n* Severe deformity or ligament insufficiency likely to require constraint\n* Inability to comply with the required follow-up assessments or complete PROMs\n* Contraindications to any aspect of the surgical technique",{"count":433,"type":21},346,[24],"The goal of this clinical trial is to learn if the VELYS Robotic-Assisted Solution (VRAS) device helps to improve outcomes from total knee replacement, when compared to regular non-robotic-assisted total knee replacement in the treatment of osteoarthritis. It will also aim to review the longer-term safety and efficiency effects of using this device.\n\nThe main questions it aims to answer are:\n\n1. Does VRAS device-assisted total knee replacement improve patient outcomes (such as their function, satisfaction, and pain) when compared to non-robotic-assisted total knee replacement?\n2. Does VRAS device-assisted total knee replacement improve clinical outcomes (such as revision risk, complications, and hospital length of stay) when compared to non-robotic-assisted total knee replacement?\n3. Does VRAS device-assisted total knee replacement improve functional outcomes (including biomechanical motion analysis) when compared to non-robotic-assisted total knee replacement?\n4. What are the economic and efficiency effects of VRAS device-assisted total knee replacement compared to non-robotic-assisted total knee replacement?\n5. What are the human factor and learning curve effects of introducing VRAS device-assisted total knee replacement into healthcare teams?\n6. Are there any differences in safety and adverse event incidence between VRAS device-assisted total knee replacement and non-robotic-assisted total knee replacement?\n\nParticipants will:\n\n* Be randomised to receive a total knee replacement using either regular non-robotic-assisted methods, or with the use of the VRAS device.\n* Be assessed pre-operatively at the clinic, and then at 6 weeks, 6 months, and 12 months following date of operation. At these appointments patients will answer questionnaires, receive an x-ray (pre-operatively, and at 6 months post-operatively), and a subgroup will be reviewed in the motion analysis laboratory (pre-operatively, and at 6 months post-operatively).\n* Have their longer-term outcomes including any revision operations monitored out to 10 years through national registry data linkage (no actual follow-up for patients after 12 months).",[437,438,439,440,441,442,443],"Knee Osteoarthritis","Osteoarthritis (Knee)","Osteo Arthritis of the Knee","Osteo Arthritis","Osteoarthritis (OA)","Osteoarthritis","Osteoarthritis in the Knee",[445,442,446,447],"Knee","Robotic","Alignment","2026-04-28",{"date":450,"type":33},"2026-05-04",{"date":364,"type":21},{"date":453,"type":21},"2030-05-08",{"name":455,"class":456},"Golden Jubilee National Hospital","OTHER_GOV",{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":283,"enrollmentInfo":465,"targetDuration":4,"studyType":22,"phases":467,"briefSummary":468,"conditions":469,"keywords":471,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":483},"100534115","phase-2-cannabidiol-for-postoperative-opioid-reduction-in-primary-total-knee-arthroplasty-100534115","NCT06234631","Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty","Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty - a Randomized, Two by Two Factorial, Double-blind, Placebo-controlled Clinical Trial","CORK","Inclusion Criteria:\n\n* Willing and able to read, understand, and sign the informed consent (English)\n* Willingness to participate in all study measures and restrictions, including patient-reported outcomes and longitudinal follow-up\n* Scheduled for surgery: primary total knee arthroplasty\n* Primary diagnosis of osteoarthritis of the surgical knee\n* Individuals of reproductive potential must agree to use acceptable birth control (defined in manual of operating procedures). This includes currently practicing an effective form of two types of birth control for women of childbearing potential, which are defined as those, alone or in combination, that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly from the screening visit until 28 days after the last study drug administration.\n* Participants must also agree not to donate sperm or eggs during study drug administration\n* Ability to take and to swallow the study medication and be willing to adhere to the treatment regimen\n* Agreement to adhere to Lifestyle Considerations (see protocol) throughout study duration\n\nExclusion Criteria:\n\n* Revision or bilateral total knee arthroplasty\n* Individuals receiving or actively applying for worker's compensation or disability and other aspects associated with potential secondary gain (postoperative disability for recovery is permitted)\n* Severe physical impairment or clinically significant illness (e.g., blindness, paraplegia)\n* Co-morbid medical conditions that may significantly impair physical functional status (e.g., current non-skin malignancies, solid organ transplant in the past year)\n* Illicit drug use (other than cannabis). Unreported opioid use would be exclusionary but reported prescribed opioid use is allowed (e.g. patient denies opioid use but is found to be positive on the urine drug screen)\n* Self-reported use of cannabis products within the 7 days prior to starting study drug\n* Self-reported use of cannabis products within the 8-30 days prior to starting study drug AND either a failed drug screen or inability to confirm successful washout (Note - may be rescreened with appropriate wash-out period)\n* High daily preoperative opioid dose\n* Individuals with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain injury\u002Fhead injury, and seizures\n* Individuals with significant illness (e.g., cancer) and\u002For clinically significant labs (e.g. labs measured by complete blood count (CBC) and basic chemistry with values meaningfully outside of the normal range \\[abnormal levels to be reviewed by the Principal Investigator or prescribing provider\\])\n* Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., psychosis, suicidal ideation; note that stable anxiety and depression are not exclusions)\n* Pregnant or nursing women (total joint arthroplasty is typically not indicated in this group of patients)\n* Self-reported liver cirrhosis\n* Self-reported uncontrolled diabetes\n* Self-reported active hepatitis (any etiology, including infectious, autoimmune, or alcohol-related)\n* Blood pressure at screening above 180 millimeters of mercury (mmHg) systolic and\u002For 120 mmHg diastolic; if value exceeds the set point, potential participants will have repeat assessment within 5 minutes for up to two additional measurements.\n* Resting heart rate at screening less than 50 beats per minute (bpm) or greater than 100 bpm; if value exceeds the set point, potential participants will have repeat assessment within 5 minutes for up to two additional measurements.\n* Elevated liver enzymes and bilirubin (measured by blood test at screening)\n* Serum total bilirubin ≥ 2.5 milligrams (mg) per deciliter (dL) (mg\u002FdL); or,\n\n  * Alanine transaminase (ALT) or Alanine transaminase (AST) ≥ 3x upper limit normal (ULN); or,\n  * Alkaline phosphatase ≥ 2x ULN\n* Severe cardiovascular disease (e.g., current unstable angina, current congestive heart failure, or current severe valvular abnormalities) that is self-reported by patient or in medical record\n* Current valproate, clobazam, or warfarin use per self-report or medical records\n* Current use of strong inducers of cytochrome p450 (CYP) enzymes CYP3A4 and CYP2C19, or CYP2C19 substrates with a narrow therapeutic index\n* Self-reported allergies to sesame oil, strawberries, opioids, or cannabis\u002Fcannabinoids and confirmed by the investigator during screening\n* Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol\n* Self-reported severe side effects to opioids precluding the use of opioids for post-surgical pain and\u002For clear plan not to use any opioids after surgery and confirmed by the investigator during screening\n* Participation in other clinical trials over the course of this study (note: outside of active period is permissible as determined by the investigator during screening)",{"count":466,"type":21},380,[81],"The goal of this study is to better understand how daily treatment with cannabidiol (CBD) affects the need for opioid pain medication, as well as pain, inflammation and other related symptoms, after knee replacement surgery. The information collected in this study is necessary to help understand whether CBD may be a useful medication before and\u002For after surgery.\n\nThe study hypothesis is that CBD exerts opioid-sparing effects through anti-inflammatory, analgesic, and anxiolytic mechanisms.",[470,27],"Knee Replacement Surgery",[472,473],"Epidiolex","Pain medication","2026-04-12",{"date":476,"type":33},"2026-04-15",{"date":478,"type":33},"2024-03-13",{"date":480,"type":21},"2029-01",{"name":482,"class":40},"Chad Brummett",2,{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":22,"phases":493,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":41},"100633907","feasibility-of-good-boost-for-adults-awaiting-total-knee-replacement-100633907","NCT07532785","Feasibility of Good Boost+ for Adults Awaiting Total Knee Replacement","Feasibility of a Community-Based Aquatic Exercise and Peer Support Intervention (Good Boost+) for Adults on Knee Replacement Waiting Lists: A Randomised Hybrid Type 1 Effectiveness-Implementation Feasibility Trial","Inclusion Criteria:\n\nAged 18 years or over. Registered on a wait list for primary total knee replacement with sufficient time to complete the 6 week intervention and follow up assessments prior to surgery.\n\nModerate self reported intensity knee joint pain within the previous month, defined as ≥4 but \\\u003C10 on the 11 point Numeric Pain Rating Scale (NPRS: 0 = no pain, 10 = worst pain imaginable).\n\nWilling and able to participate in a six week programme of weekly group water-based exercise at specified leisure centre swimming pools in Southwark and three times weekly land-based exercise training in a private setting.\n\nWilling to pay £4.30 for water-based exercise sessions 5 \\& 6. This fee is in line with the usual cost of over 60s group exercise classes at local leisure centres.\n\nAccess to a smart phone or tablet computer with internet access. Willing and able to accept either trial arm allocation. Willing and able to give informed consent.\n\nExclusion Criteria:\n\nIndividuals scheduled to have another major joint replacement (e.g. contralateral knee, hip or shoulder) within the study period.\n\nIndividuals on the waiting list for revision surgery of a previous knee replacement.\n\nIndividuals with active inflammatory arthritis (e.g., RA, PsA, lupus, axial SpA) that is clinically symptomatic or requires ongoing immunosuppressive therapy to control disease activity.\n\nIndividuals who self-report being advised by a healthcare professional not to exercise.\n\nIndividuals who have previously participated in water-based exercise sessions delivered via the Good Boost HUB application.\n\nParticipating or planning to participate in another interventional clinical study\u002Ftrial during the study period that in the opinion of the investigator could affect the outcomes of this study.\n\nIndividuals unable to understand written or spoken English or communicate sufficiently well in English to participate despite assistance from a family member or friend.\n\nIndividuals unable to comply with the protocol \u002F requirements of study participation.\n\nIndividuals with any other severe concomitant disease that, in the opinion of the investigator might interfere with trial procedures and\u002For assessments.",{"count":492,"type":21},48,[24],"The goal of this randomised controlled feasibility trial is to find out whether it is possible to run a larger study of the Good Boost+ community based rehabilitation programme for people waiting for a primary total knee replacement.\n\nThe study will look at how many people are willing to take part, whether they stay in the study, and whether they can follow the Good Boost+ programme as planned. It will also explore how acceptable the programme is to patients, NHS staff and leisure centre staff, and which outcome measures are most useful for a future full scale trial. The study will also look at what helps or hinders delivery of the programme in real world NHS and community settings.\n\nThe main questions it aims to answer are:\n\n* How many people waiting for knee replacement surgery are willing to take part in the study\n* Whether participants can continue with the Good Boost+ programme as planned over the study period\n* Which outcome measures best capture any potential benefits of the programme\n* How acceptable the programme is to patients, NHS and leisure centre staff\n* What helps or makes it difficult to deliver the programme in practice.\n\nParticipants will be randomly assigned to one of two groups.\n\n* Usual NHS care or\n* Usual NHS care plus the Good Boost+ programme\n\nParticipants in the Good Boost+ programme will take part in six weekly group water based exercise sessions held in local swimming pools, as well as land based exercise sessions that can be done individually or by joining a virtual group. The exercise sessions are delivered through Good Boost's digital technology, using small waterproof tablet computers at swimming pools, and smartphones or computers for land-based sessions. Physiotherapy staff will provide guidance throughout, and volunteers will offer refreshments after pool sessions to support social connection.\n\nAll participants, including those receiving usual NHS care only, will be asked to complete an exercise diary, rate their knee pain each week, and complete short questionnaires at 6 and 10 weeks after joining the study.",[438,496],"Arthroplasties, Knee Replacement",[498,499,500,501,502],"Total Knee Replacement","Prehabilitation","Feasibility","Randomised controlled trial","Implementation","2026-04-09",{"date":505,"type":33},"2026-04-16",{"date":507,"type":21},"2026-06",{"date":509,"type":21},"2028-02",{"name":511,"class":40},"King's College Hospital NHS Trust",{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":22,"phases":521,"briefSummary":522,"conditions":523,"keywords":524,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":41},"100528275","mechanically-or-kinematically-aligned-total-knee-prosthesis-100528275","NCT06158646","Mechanically or Kinematically Aligned Total Knee Prosthesis","Mechanically or Kinematically Aligned Total Knee Prosthesis: Prospective and Comparative Study of Clinical, Stereoradiographic, and Biomechanical Results","BIOMAKA","Inclusion Criteria:\n\n* Patient followed as part of a consultation 1 year after TKA placement\n* Adult patient\n* Patient affiliated to a social security system\n* Patient informed of the study and formally included (signing of informed consent) before the first research review\n\nExclusion Criteria:\n\n* Patient with a contralateral knee prosthesis\n* Patient with another condition (acquired pathology) of the lower limbs (e.g. severe osteoarthritis of the contralateral knee or hip\u002Fankle) and\u002For of the nervous system (e.g. Parkinson's) which may significantly affect the quality of walking\n* Pregnant patient\n* Patient deprived of liberty by judicial or administrative decision,\n* Adult patient subject to a legal protection measure or unable to express consent",{"count":237,"type":21},[24],"The mechanical alignment technique (Mechanical Alignment - MA) of a total knee prosthesis (TKA) was developed with the aim of making the installation of a TKA simple and reproducible, and that the prosthetic biomechanics are acceptable, thus promoting good longevity of implants. This is a technique that does not aim to restore the constitutional anatomy of the knee; bone cuts are systematically made at fixed angles, in the 3 planes of space, in relation to the mechanical axes of the long bones (femur and tibia). This non-personalized implantation technique therefore systematically alters the anatomy, laxity and kinematics of the knee, causing up to 50% of residual symptoms after prosthetic implantation and 20% of dissatisfied patients.\n\nIn order to improve the clinical results of TKA, a new, more personalized and physiological technique was developed in 2007, called Kinematic Alignment (KA). This technique aims to restore the pre-arthritic anatomy, unique to each knee. Patients with severe constitutional deformity of the lower limb therefore retain this deformity after kinematic prosthetic replacement. The impact of the alignment technique on the biomechanics of the prosthetic knee remains poorly described. The main objective of this study is therefore to compare knee biomechanics between mechanical TKA and kinematic TKA.",[27],[525,526,527,528],"total knee prosthesis","mechanical alignment","kinematic alignment","biomechanic study","2026-03-31",{"date":531,"type":33},"2026-04-06",{"date":533,"type":33},"2023-10-05",{"date":535,"type":21},"2027-09-30",{"name":537,"class":40},"Clinique du Sport, Bordeaux Mérignac",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":328,"enrollmentInfo":546,"targetDuration":4,"studyType":382,"phases":4,"briefSummary":548,"conditions":549,"keywords":553,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":41},"100514587","comparative-study-of-navigation-assisted-orthopilot-elite-and-robotic-assisted-mako-total-knee-arthroplasty-100514587","NCT05980442","Comparative Study of Navigation-assisted OrthoPilot® Elite and Robotic-assisted MAKO® Total Knee Arthroplasty","Randomized, Controlled, Single Center Observational Study to Compare the Safety and Performance of Navigation-assisted OrthoPilot® Elite and Robotic-assisted MAKO® Total Knee Arthroplasty","ORMAK","Inclusion Criteria:\n\n* Indication for a TKA with a fixed-bearing total knee endoprosthesis\n* Written informed consent for participating in the clinical study\n\nExclusion Criteria:\n\n* Patient age \\\u003C18 years and \\>90 years\n* Patient not willing to participate at the follow-up\n* Pregnancy\n* retropatellar arthrosis requiring patella resurfacing\n* American Society of Anaesthesiologists (ASA) Classification \\>3",{"count":547,"type":21},140,"Randomized, controlled, single center observational study to compare the safety and performance of navigation-assisted OrthoPilot Elite and robotic-assisted MAKO total knee arthroplasty (TKA). The aim of the study is the comparison of the clinical outcome between navigated and robotic-assisted TKA. The hypothesis of the study is that both treatments achieve similar results regarding functional and clinical aspects.",[27,550,551,552],"Joint Diseases","Rheumatoid Arthritis of Knee","Posttraumatic Arthropathy",[554,555,556,312,557],"computer assisted orthopedic surgery","robotic assisted orthopedic surgery","orthopedic navigation","total knee replacement","2026-03-26",{"date":560,"type":33},"2026-03-27",{"date":562,"type":33},"2024-07-03",{"date":564,"type":21},"2028-12",{"name":566,"class":93},"Aesculap AG",{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":17,"minAge":122,"maxAge":283,"enrollmentInfo":574,"targetDuration":4,"studyType":22,"phases":576,"briefSummary":578,"conditions":579,"keywords":580,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":4},"100474182","phase-1-a-study-evaluating-the-safety-tolerability-and-activity-of-icm-203-in-subjects-with-knee-osteoarthritis-100474182","NCT05454566","A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.","A Single Dose Escalation Study of Intra-Articular ICM-203 in Subjects With Kellgren-Lawrence Grade 2 or Grade 3 Osteoarthritis of the Knee","Inclusion Criteria:\n\n1. Body mass index (BMI) of 18.0 to 40.0 kg\u002Fm2, inclusive, at the time of screening.\n2. Kellgren-Lawrence grade 2 or grade 3 OA of target knee.\n3. Target knee pain between 4 and 9, inclusive, on an NRS ranging from 0 (no pain) to 10 (worst pain imaginable), at the time of screening.\n4. KOOS function in daily living score \\>25, a measure of knee function ranging from 0 (extreme problems) to 100 (no problems), at the time of screening .\n5. A stable treatment regimen for symptomatic relief of OA, including NSAIDs, for 4 weeks prior to screening.\n\nExclusion Criteria:\n\n1. History of rheumatoid arthritis, psoriatic arthritis, gout, pseudogout, autoimmune OA, chondrocalcinosis, hemochromatosis, villonodular synovitis, and synovial chondromatosis or other disorder that in the opinion of the Investigator could cause inflammation of the knee.\n2. Injection of steroid, hyaluronate or other agent, into the target knee less than 90 days prior to day 1.\n3. Major injury to the target knee, such as torn ligament or severe sprain, within 12 months of screening.\n4. Disability so severe that the subject cannot comply with the study requirements, including knee symptoms that result in significant difficulty or inability to walk.\n5. Surgery on the target knee within 180 days prior to day 1.\n6. Total knee arthroplasty or other knee surgery planned in the next 12 months.\n7. Active joint infection or other concurrent medical or psychiatric condition that, in the opinion of the Investigator, would make the subject unsuitable for the study.",{"count":575,"type":21},18,[577,81],"PHASE1","The purpose of this study is to determine the safety, tolerability, and activity of ICM-203, a recombinant adeno-associated viral (AAV) vector that expresses a therapeutic gene that promotes cartilage formation, reduces joint inflammation and pain, as well as improves joint physical function, by injecting escalating doses of ICM-203 into the knee of subjects with mild to moderate knee osteoarthritis (OA).\n\nApproximately 6 to 18 subjects will be enrolled into 3 successive dose-escalating groups in a 3+3 study design, whereby 3 study subjects in each group will be dosed sequentially with ICM-203 and 3 additional subjects will be dosed at the same dose level if a dose limiting toxicity (DLT) occurs in any of the first 3 subjects.",[27],[581,582,583,360],"adeno-associated virus","gene therapy","ICM-203","2026-03-25",{"date":560,"type":33},{"date":587,"type":21},"2026-11-15",{"date":589,"type":21},"2028-11-15",{"name":591,"class":93},"ICM Co. Ltd.",{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":17,"minAge":379,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":22,"phases":601,"briefSummary":602,"conditions":603,"keywords":604,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":41},"100626741","wound-closure-materials-and-techniques-in-hip-and-knee-arthroplasty-100626741","NCT07439575","Wound Closure Materials and Techniques in Hip and Knee Arthroplasty","Evaluation of Different Suture Materials and Closure Techniques in Lower Extremity Arthroplasty: Effects on Wound Healing, Functional Outcomes, and Complications","Inclusion Criteria:\n\n* Age ≥ 30 years\n* Patients undergoing primary total hip arthroplasty or total knee arthroplasty\n* Patients undergoing aseptic revision total hip or knee arthroplasty\n* Surgery performed by the same surgical team\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 30 years\n* Patients receiving immunosuppressive therapy\n* Patients with complicated diabetes mellitus\n* Chronic venous insufficiency\n* Peripheral arterial disease\n* Arthroplasty performed due to malignancy\n* Active or previous surgical site infection",{"count":600,"type":21},90,[24],"This prospective randomized clinical study aims to evaluate the effects of different suture materials and wound closure techniques on wound healing, functional outcomes, and postoperative complications in patients undergoing total hip and knee arthroplasty.\n\nA total of at least 90 adult patients undergoing primary or aseptic revision lower extremity arthroplasty will be randomized into two groups according to the wound closure material and technique used. All surgeries will be performed by the same surgical team following standardized operative protocols.\n\nPrimary outcomes include wound-related complications such as prolonged wound drainage, wound dehiscence, surgical site infection, and local inflammatory findings within 90 days postoperatively. Secondary outcomes include operative time, bleeding amount, cosmetic outcomes, and functional scores.\n\nThe results of this study are expected to help determine the most effective and safe wound closure method in lower extremity arthroplasty.",[27,407],[195,605,606,607,608,609,336],"Total Hip Arthroplasty","Wound Closure","Barbed Suture","Surgical Site Infection","Wound Healing","2026-02-26",{"date":612,"type":33},"2026-03-02",{"date":614,"type":33},"2025-11-01",{"date":616,"type":21},"2026-08",{"name":618,"class":456},"Bahattin Kemah",{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":625,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":17,"minAge":122,"maxAge":627,"enrollmentInfo":628,"targetDuration":4,"studyType":22,"phases":630,"briefSummary":631,"conditions":632,"keywords":633,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":41},"100497728","phase-4-helping-osteoarthritis-patients-to-walk-with-nsaid-100497728","NCT05761015","Helping Osteoarthritis Patients to Walk With NSAID","A Rehabilitation Walking Program With the Help of a Transient Intake of Nonsteroidal Anti-inflammatory Drug for Patients With Painful Hip\u002FKnee Osteoarthritis - A Pilot Cohort Study With Objectives of Short Walks in the Real Life.","PERIPATEI","Inclusion Criteria:\n\n* Uni- or bilateral hip or knee idiopathic osteoarthrosis (ACR criteria, Kellgren-Lawrence grade 2 or more on recent X-ray), responsible for pain since 3 at least months, and pain at walking which intensity is at least 4\u002F10 on a numerical rating scale.\n* Less than 3 relevant walks (at least 20 minutes or 1000 km) a week.\n* Ability to understand and to follow the protocol, and to answer the questionnaires\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Legal protection\n* Body weight \\\u003C 40 kg or underweight\n* Body weight \\>120 kg or obesity\n* Unability to walk, or unability to walk without support devices (sticks, crutches, orthoses and knee pads are allowed)\n* Secondary osteoarthrosis (rheumatism, septic arthritis, recent osteonecrosis, hemochromatosis, gout, acromegalia…).\n* Concomitant general bone disease (Paget, Reiter…).\n* Concomitant and relevant painful disease else than due to osteoarthrosis (e.g. neuropathic pain, fibromyalgia…)\n* Previous recent intervention (e.g. surgery, arthroscopy, joint infiltration) expected to relief osteoarthrosis pain throughout the study period.\n* Planned intervention similar to those abovementioned, during the study period.\n* Recent initiation of any new analgesic treatment (including systemic steroids).\n* Planned initiation of any program expected to relief osteoarthrosis pain during the study period, such as physiotherapy, cognitive behavioral therapy…).\n* Planned major surgery during the study period.\n* Current cancer disease.\n* Immunosuppression.\n* Autoimmune disease.\n* Concomitant topical or systemic NSAID treatment.\n* Chronic strong opioid intake.\n* Concomitant insulin therapy.\n* Any absolute or relevant contraindication to NSAIDs or acetaminophen, according to the French drug agency","70 Years",{"count":629,"type":21},55,[239],"There is a lack of effective analgesic treatments to help walking patients with painful hip\u002Fknee osteoarthritis. Our team therefore imagined a new strategy lying on a multimodal rehabilitation walking program with the help of a transient intake of nonsteroidal anti-inflammatory drug (NSAID). NSAIDs are indeed known to act specifically on pain at movement, but their continuous intake would induce unacceptable side effects. To optimize the benefit\u002Frisk balance, the molecule to be chosen must fit to the patient's profile, and its intake should cover only the period of interest, i.e. planned walks. Our multimodal rehabilitation program will also include physical techniques such as appropriate footwear, a patient's education aiming at reducing fear\u002Favoidance and spotting side effects of NSAIDs, and a prescription frame to avoid any overdosing.\n\nThis clinical study is a single-center, non-randomized, open label, one-arm trial, using drugs prescribed according to their label (i.e. osteoarthritis pain), pending a reinforced monitoring of side effects.\n\nThe primary endpoint is to evaluate efficacy and tolerance of a tailored and transient administration of NSAID within a rehabilitation walking program in patients with painful hip\u002Fknee osteoarthritis.\n\nSecondary endpoints are to evaluate the adherence to the program and the factors influencing adherence; to identify the less well tolerated conditions of treatment (one condition being one molecule for one patient profile); to identify the factors of success among a set of baseline demographic, morphometric and psychometric variables; and to study the role of central sensitization (assessed by temporal summation) on the efficacy of treatment.",[27,407,151],[27,407,634,635,636,637,638,639],"pain at movement","nonsteroidal anti-inflammatory drug","acetaminophen","paracetamol","personalized medicine","pharmacovigilance","2026-02-24",{"date":642,"type":33},"2026-02-27",{"date":644,"type":33},"2023-12-14",{"date":646,"type":21},"2028-04",{"name":648,"class":40},"University Hospital, Clermont-Ferrand"]